← Back to Screener
Maze Therapeutics, Inc. Common Stock (MAZE)
Price$24.27
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-43.63%
Price vs S&P 500 (4W)-6.75%
VGM Score42.78
Market Capitalization$1.34B
P/E Ratio (Annual)77.66x
All Metrics
P/CF (Annual)18.79x
Book Value / Share (Quarterly)$6.87
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.46
Price vs S&P 500 (YTD)-49.58%
EPS (TTM)$-2.52
10-Day Avg Trading Volume0.43M
EPS Excl Extra (TTM)$-2.52
EPS (Annual)$-3.05
ROI (Annual)-36.94%
Cash / Share (Quarterly)$7.08
P/E Normalized (Annual)77.66x
ROA (Last FY)-33.02%
EBITD / Share (TTM)$-2.68
Cash Flow / Share (Annual)$-2.29
P/B Ratio3.93x
P/B Ratio (Quarterly)4.34x
Net Income / Employee (Annual)$-929,900
Net Interest Coverage (TTM)13.77x
ROA (TTM)-31.78%
EPS Incl Extra (Annual)$-3.05
Current Ratio (Annual)15.50x
Quick Ratio (Quarterly)17.54x
3-Month Avg Trading Volume0.75M
52-Week Price Return81.93%
EV / Free Cash Flow (Annual)14.84x
Revenue / Employee (TTM)$141,800
P/S Ratio (Annual)8.02x
Asset Turnover (Annual)0.70x
52-Week High$53.65
EPS Excl Extra (Annual)$-3.05
26-Week Price Return-35.71%
Quick Ratio (Annual)15.16x
13-Week Price Return-46.42%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)17.88x
Enterprise Value$1.18B
Revenue / Employee (Annual)$0
Pretax Margin (Annual)31.88%
Cash / Share (Annual)$6.93
3-Month Return Std Dev84.32%
Net Income / Employee (TTM)$-869,100
ROE (Last FY)-36.94%
EPS Basic Excl Extra (Annual)$-3.05
Total Debt / Equity (Quarterly)0.11x
EPS Incl Extra (TTM)$-2.52
ROI (TTM)-35.59%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)57.57%
Year-to-Date Return-41.42%
5-Day Price Return-4.67%
EPS Normalized (Annual)$-3.05
Net Profit Margin (Annual)10.97%
Month-to-Date Return-8.28%
EBITD / Share (Annual)$-3.27
Operating Margin (Annual)34.38%
LT Debt / Equity (Annual)0.00x
LT Debt / Equity (Quarterly)0.11x
EPS Basic Excl Extra (TTM)$-2.52
P/B Ratio (Annual)5.62x
Book Value / Share (Annual)$7.19
Price vs S&P 500 (13W)-54.68%
Beta1.10x
P/FCF (Annual)17.96x
Revenue / Share (TTM)$0.37
ROE (TTM)-36.63%
52-Week Low$9.83
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.45est. -0.56
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.33
4.33
4.33
4.33
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MAZEMaze Therapeutics, Inc. Common Stock | — | — | C | $24.27 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Maze Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for chronic kidney disease, cardiovascular disease, and obesity using its proprietary Compass platform. The platform identifies disease-causing genetic variants and links them to underlying biological pathways, enabling targeted therapeutic development. The company is advancing two lead programs—MZE829 and MZE782—both designed to treat chronic kidney disease.